Product CandidatesOur platform allows us to initiate a structured process for discovering biomarkers for high-value market opportunities in healthcare that we identify in conjunction with our partners. As part of our product development process for internally discovered and licensed biomarkers, we develop and optimize our own first generation assays, conduct clinical development studies utilizing these tests and then seek regulatory clearance or approval if the clinical studies are successful. We seek partnerships with leading diagnostic laboratory instrument manufacturers for the development and commercialization of our products on their platforms. We believe that focusing on novel content for existing automated laboratory instruments will facilitate broader and more rapid adoption of our diagnostic tests.
* The BGM Galectin-3 Test (pending 510(k)) is not available for sale within the United States and is not authorized for sale in Canada. |